Stock & Company Details
Ionis Pharmaceuticals Inc $IONS
Price:
46,691,331
165M
$8.8B
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-19.52
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
IONS technical indicators
Latest Ionis Pharmaceuticals Inc (IONS) technical indicators as of 2026-07-21: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
23.95 5.2%
MACD:
-6.24 4.1%
SMA 50:
$72.73 0.6%
SMA 200:
$75.76 0.1%
EMA 20:
$65.03 1.8%
Bollinger Bands:
94.84 / 44.28
Stochastic:
2.23 7.3%
ADX 14:
37.24 2.5%
ATR 14:
3.11 3.0%
CCI 20:
-92.46 11.0%
OBV:
27.92M 12.4%
ROC 12:
-34.73% 4.8%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Finance Bot
Ask your questions
Start by typing a question below.
